J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating today.
Anupam Rama has given his Buy rating due to a combination of factors that highlight the long-term potential of Sarepta Therapeutics. Despite the company’s recent earnings report showing a miss in expected revenue for Elevidys and a downward revision in guidance, Rama believes that the market’s reaction is overly pessimistic and does not accurately reflect the company’s fundamentals.
Anupam Rama emphasizes the promising future of Sarepta’s Elevidys and the company’s expanding pipeline as key reasons for maintaining an optimistic outlook. The analyst suggests that while current challenges exist, the underlying growth prospects and strategic developments position Sarepta favorably for future success. This long-term view underpins the Buy rating, indicating confidence in the company’s ability to overcome short-term hurdles and capitalize on its innovative therapies.
Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Neurocrine, and Ultragenyx Pharmaceutical. According to TipRanks, Rama has an average return of -3.9% and a 39.80% success rate on recommended stocks.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $113.00 price target.